NO941738L - Fremgangsmåte for inhibering av restenose - Google Patents

Fremgangsmåte for inhibering av restenose

Info

Publication number
NO941738L
NO941738L NO941738A NO941738A NO941738L NO 941738 L NO941738 L NO 941738L NO 941738 A NO941738 A NO 941738A NO 941738 A NO941738 A NO 941738A NO 941738 L NO941738 L NO 941738L
Authority
NO
Norway
Prior art keywords
growth factor
derivatives
site
cyclodextrin
low solubility
Prior art date
Application number
NO941738A
Other languages
English (en)
Norwegian (no)
Other versions
NO941738D0 (no
Inventor
Howard C Herrmann
Elliot Barnathan
Paul B Weisz
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL10002391A external-priority patent/IL100023A/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of NO941738D0 publication Critical patent/NO941738D0/no
Publication of NO941738L publication Critical patent/NO941738L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
NO941738A 1991-11-11 1994-05-10 Fremgangsmåte for inhibering av restenose NO941738L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL10002391A IL100023A (en) 1991-11-11 1991-11-11 Pharmaceutical composition comprising a cyclodextrin derivative for the inhibition of undesired smooth muscle cell growth following angioplasty
US79032091A 1991-11-12 1991-11-12
US90059292A 1992-06-18 1992-06-18
PCT/US1992/009754 WO1993009790A1 (en) 1991-11-11 1992-11-10 Methods of inhibiting restenosis

Publications (2)

Publication Number Publication Date
NO941738D0 NO941738D0 (no) 1994-05-10
NO941738L true NO941738L (no) 1994-07-11

Family

ID=27271521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941738A NO941738L (no) 1991-11-11 1994-05-10 Fremgangsmåte for inhibering av restenose

Country Status (8)

Country Link
EP (1) EP0612249A4 (sv)
JP (1) JPH07500843A (sv)
AU (1) AU678760B2 (sv)
BR (1) BR9206736A (sv)
CA (1) CA2124857A1 (sv)
FI (1) FI942166A (sv)
NO (1) NO941738L (sv)
WO (1) WO1993009790A1 (sv)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69322721T2 (de) * 1992-09-24 1999-06-10 Terumo Corp Sulfonierte Verbindungen aus Beta-Cyclodextrinpolymer und diese enthaltendes Medikament welches die Hyperplasie von Gefässwanden hemmt
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US5464827A (en) * 1994-06-20 1995-11-07 American Home Products Corporation Esterified polyanionic cyclodextrins as smooth muscle cell proliferation inhibitors
US5498775A (en) * 1994-11-07 1996-03-12 American Home Products Corporation Polyanionic benzylglycosides as inhibitors of smooth muscle cell proliferation
US5773420A (en) * 1994-11-07 1998-06-30 American Home Products Corporation Acylated benzylglycosides as inhibitors of smooth muscle cell proliferation
US5565432A (en) * 1994-11-07 1996-10-15 American Home Products Corporation Smooth muscle cell proliferation inhibitors
WO1997039761A1 (en) * 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
AUPO888497A0 (en) * 1997-09-01 1997-09-25 Australian National University, The Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7081448B2 (en) 1998-11-24 2006-07-25 Wyeth Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
US6291434B1 (en) 1998-11-24 2001-09-18 American Home Products Corp. Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation
US6258784B1 (en) 1998-11-24 2001-07-10 American Home Products Corp. Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
US6362170B1 (en) 1998-11-24 2002-03-26 American Home Products Corporation Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
US6340670B1 (en) 1998-11-24 2002-01-22 American Home Products Corporation Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
US6664243B1 (en) 1998-11-24 2003-12-16 Wyeth Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
US7132402B2 (en) 1998-11-24 2006-11-07 Wyeth Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
US6339064B1 (en) 1998-11-24 2002-01-15 American Home Products Corporation Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
US6451767B1 (en) 1998-11-24 2002-09-17 Wyeth Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation
US6187755B1 (en) 1998-11-24 2001-02-13 American Home Products Corporation Benzylmaltosides as inhibitors of smooth muscle cell proliferation
FR2811572B1 (fr) * 2000-07-17 2003-04-18 Adir Utilisation de cyclodextrines polysulfatees pour le traitement de l'arthrose
FR2827799A1 (fr) * 2001-07-27 2003-01-31 Sofradim Production Endoprothese vasculaire recouverte d'un derive fonctionnalise de dextrane et son procede de preparation
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
FR2923391B1 (fr) * 2007-11-08 2012-07-27 Biocydex Compositions pour conserver des cellules, des tissus ou des organes, procede d'obtention et utilisations.
KR20110067130A (ko) * 2008-09-22 2011-06-21 아카리오스 비.브이. 약제로서 유용한 카르복시에틸화 사이클로덱스트린 폴리설페이트
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020160A (en) * 1975-08-15 1977-04-26 American Cyanamid Company Cyclodextrin sulfate salts as complement inhibitors
ATE82126T1 (de) * 1986-04-04 1992-11-15 Angiogenics Ltd Zubereitung zum stoppen von angiogenese und einem kapillar-, zellen- oder membranleck.
CA1333363C (en) * 1988-01-19 1994-12-06 Judah Folkman Angiogenesis inhibitor comprising fumagillin
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
US5482929A (en) * 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor

Also Published As

Publication number Publication date
EP0612249A1 (en) 1994-08-31
AU678760B2 (en) 1997-06-12
WO1993009790A1 (en) 1993-05-27
FI942166A0 (sv) 1994-05-10
BR9206736A (pt) 1995-10-31
NO941738D0 (no) 1994-05-10
EP0612249A4 (en) 1995-11-08
FI942166A (sv) 1994-07-08
AU3074292A (en) 1993-06-15
JPH07500843A (ja) 1995-01-26
CA2124857A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
NO941738L (no) Fremgangsmåte for inhibering av restenose
ES2187719T3 (es) Derivados difluoroprostaglandinas y su aplicacion.
WO1997029779A3 (en) EGF-Genistein conjugates for the treatment of cancer
CA2119154A1 (en) Derivatives of Cyclodextrins Exhibiting Enhanced Aqueous Solubility and the Use Thereof
PT840621E (pt) Adesivos com hormonas
NO954119D0 (no) Fremgangsmåte for å frembringe en modell av den romlige fordeling av geometriske objekter i et miljö, slik som forkastninger i en geologisk formasjon
WO2000074633A3 (en) Method and apparatus for adjusting flexible areal polymer implants
DE60042369D1 (de) Chemisch programmierbare immunität
ATE108656T1 (de) Angiotensin-ii-receptoren-blocker zur behandlung der cardialen hypertrophie.
WO1992020336A3 (en) Novel cholesterol lowering compounds
NO20002676D0 (no) Androgene steroidforbindelser og en fremgangsmÕte for fremstilling og anvendelse av samme
NO20013632L (no) Steroid sulfatase inhibitorer og fremgangsmater for fremstilling og anvendelse av det samme
GR890100520A (en) Oval wrap suture package
AU2002215904A1 (en) Compounds with a branched linker
RU96101167A (ru) Брассиностероидное производное и его использование в качестве регулятора роста растений
DE122009000009I2 (de) Herbizide fettsäure und maleinsäurehydrazidsalze enthaltende zusammensetzungen
NO990914L (no) Amorfe benzotiofener, fremgangsmÕter for fremstilling og fremgangsmÕter for anvendelse
EP0517476A3 (en) Benzimidazole derivatives, a method for producing the same, agricultural and horticultural fungicides containing the same as an active ingredient and intermediate compounds thereof
AU8773491A (en) Benzimidazole derivative, a method for producing the same, its intermediate compounds and an agricultural and horticultural fungicide containing the benzimidazole derivative as an active ingredient
NL7904232A (nl) Werkwijze en inrichting voor de bereiding van zwelbare, verknoopte carboxyalkylcellulose uit natuurlijke cellulose of celulosehydraat alsmede de toepassing van een aldus bereide carboxyalkylcellulose.
NO954978L (no) Fremgangsmåte for generering av hannlige planter
NO971604L (no) Orale sabeluzolsuspensjoner
NO20014934D0 (no) Plantet skog, fremgangsmåte for planting av tr¶r og fremgangsmåte for plantedyrking
EP1129712A4 (en) PREPARATIONS OF QUINOLINONE DERIVATIVES AND THEIR PRODUCTION METHOD
RU2000112600A (ru) Способ регионарной анестезии при операциях на тазобедренном суставе и бедренной кости